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Germ-Line G e n e Therapy: Another V i e w 
The circumstance of this editorial 
In May of 1992, I received a call from Dr. Nelson Wivel, 
director of the Office of Recombinant D N A Activities, inviting 
me to make a presentation to the R A C regarding the subject of 
spontaneous and induced germ-line mutation. He explained that 
in the light of all the current discussion concerning germ-line 
gene therapy, the Committee felt it needed to inform itself 
concerning germ-line gene dynamics, and the subject of muta-
tion seemed a good place to start. He was extremely careful to 
emphasize that this invitation in no wise implied that R A C 
believed germ-line therapy was imminent, but only that the 
time was at hand for this group to begin to consider the subject 
in an orderly fashion. I met with the Committee on September 
14, 1992. I had had sufficient time to consider the significance 
of the situation; after meeting my charge, I took license to 
express a personal view concerning the wisdom of that distin-
guished Committee setting up a series of briefings of this sort at 
this time. I thank the Committee for the tolerance it exhibited in 
the face of this unexpected diversion. Dr. French Anderson was 
in the audience and suggested I put those thoughts (with some 
extensions) on record in Human Gene Therapy. 
A viewpoint 
M y message to the Committee was clear and simple: The 
Committee's desire to prepare itself for future developments 
would under most circumstances be laudable, but for a Com-
mittee with this visibility and prestige to begin to consider the 
subject of germ-line therapy in an organized fashion at this time 
would send the wrong vibes to the scientific, ethical, and polit-
ical communities. Such an action might appear to imply the 
belief that the Committee would be seriously considering this 
prospect within the terms of office of present Committee mem-
bers. Given the tremendous issues at stake, and even with the 
utmost attempt on my part to anticipate the amazing speed of 
advances in the field of molecular genetics, I could not imagine 
serious organized discussions of this subject by such a group 
within the next 20 or 30 years. (Individuals will, of course, 
express their views as they please.) 
The basis for this position 
I am primarily a population geneticist. M y stance stems not 
only from that background but also from broader philosophical 
considerations. The bases for the position adopted above can be 
briefly summarized under three headings: 
1. Intellectual arrogance. The elucidation of the precise na-
ture of our genetic material, four billion years in evolving, 
occurred only 40 years ago. Despite the incredible advances in 
molecular genetics, we still have a very limited knowledge of 
the anatomy of our DNA, but even less understanding of how it 
transacts its excruciatingly complex business. Right now the 
ecosystem is reeling under the impact of an intellectual arro-
gance which assumed unbridled license to perturb that system. 
W e are a part of that ecosystem, the last frontier, so to speak. Is 
there any informed person who, surveying the current evidence 
of the profound consequences of precipitous human action, 
believes we are now ready for a serious consideration of how to 
mold ourselves genetically? 
I am perhaps the only practicing human geneticist who ever 
browsed (1941) through the files of the old Eugenics Record 
Office in Cold Spring Harbor, standard-bearer of the eugenics 
movement in the 1920s and 1930s. The naivete expressed in 
those records and by that movement defies characterization. I 
fear that two generations hence, our present-day thinking about 
germ-line gene therapy will appear as naive and misguided as 
the eugenic thinking of two generations ago. 
2. The lessons of somatic cell gene therapy. Somatic cell 
gene therapy is scarcely off the ground, its lessons yet to be 
divulged, and already some wish to consider germ-line therapy. 
Surely there is time—two, three decades—to monitor for all the 
nuances of attempts at the introduction of foreign genes into 
somatic cells, before turning to the germ line. 
With my preoccupation with the integrity of the human germ 
line, I would have to urge that there is one aspect of somatic cell 
therapy that should have high priority, namely, meticulous test-
ing for unanticipated germ-line intrusions of the vectored DNA. 
The retroviral vectors employed in such therapy have been so 
enfeebled that there would appear to be no risk that they will 
carry their therapeutic passenger gene beyond the target tissue. 
But what of adventitial transmission into the germ line due to 
passing "helper" retroviruses or contamination of the vector 
strain by non-enfeebled virus? The human haploid genome con-
tains of the order of one million sequences with greater or lesser 
homologies to retroviruses. Some of these must represent the 
footprints of viruses not specifically targeted to gonadal tissues, 
viruses which somehow strayed into the germ line. W e have 
absolutely no idea of the price the species paid for these foot-
prints. What we now see are the successful survivors—not 
those insertions resulting in genetic defect which were elimi-
nated through selection. 
While the prospects of successful germ-line intrusion in the 
course of retroviral-mediated somatic cell therapy seem slim 
(reviewed in Cometta et al., 1991), data to this effect are 
urgently needed. The use of DNA-liposome complexes for 
gene transfer would seem to lessen the likelihood of germ-line 
intrusions, and, indeed, the first relevant studies reveal no evi-
dence that DNA-liposomal transduction was accompanied by 
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uptake of plasmid D N A by gonadal tissue (Nabel et al.. in 
press). I suggest that efforts to detect gonadal intrusion by 
foreign D N A should become a standard requirement for gene 
therapy protocols; the gene therapy techniques with least evi-
dence for germ-line contamination should be the preferred tech-
niques. 
A balanced perspective in this situation demands we recog-
nize that the chemotherapy of certain childhood malignancies 
with such known mutagens as nitrogen mustard, procarbazine, 
cyclophosphamide, or doxorubicin also carried the risk of the 
induction of germ-line mutations. To a lesser extent, this poten-
tial result also holds for radiation therapy, but here genetic risks 
are reduced by gonadal shielding. As a result of these therapies, 
a substantial number of individuals who previously would have 
died during childhood are now reproducing. It would be incon-
sistent to hold somatic cell gene therapy to higher standards 
than those to which the accepted modalities are held. In fact, the 
genetic risks accompanying such chemo- and radiation therapy 
are unknown. I suggest that a major genetic study of the off-
spring of children treated either with chemotherapy/radiation or 
somatic cell gene transfer is called for. The number of children 
to be bom to these survivors is for the immediate future too 
small to yield insightful findings on the basis of the conven-
tional genetic approaches, but the emerging D N A technologies 
for the study of mutation (reviewed in Neel et al., 1993) hold 
great promise for extracting a significant body of information 
from each subject. 
3. The requirements for successful germ-line therapy. 
Anderson (1985, 1992) and Davis (1992), among others, have 
succinctly laid down two technical advances which must occur 
prior to serious consideration of germ-line therapy. The shotgun 
introduction of genes into transgenic mice is accompanied in 
about 1 0 % of "successes" by the induction of unanticipated 
genetic effects (Palmiter and Brewster, 1986). This is unaccept-
able for humans. For human germ-line therapy to be accept-
able, (i) the defective gene must be replaced by precise homol-
ogous recombination and function appropriately, and (ii) there 
must be evidence that a new genetic problem has not been 
created elsewhere in the genome, presumably by nonhomolo-
gous recombination. The necessary preliminary assurances on 
both these points must be pursued in an experimental organism, 
presumably the mouse, where the extensive body of back-
ground genetic data should facilitate the large-scale search for 
nontargeted events that the problem requires. Even in the 
mouse, meeting these requirements will not be easy, since some 
of the possible untoward effects, such as impairment of brain 
functions, may be quite subtle in a mouse (but not so subtle in a 
human). Furthermore, the careful study of the germ-line conse-
quences (if any) of somatic cell therapy in experimental ani-
mals, mentioned in the last section, will also fill this gap in 
knowledge. It is impossible to predict a time table for these 
developments. 
The desire to ameliorate the lot of humankind through both 
somatic cell and germ-line therapy is the most recent extension 
of a healing ethic applauded through the centuries. There is an 
enormous amount of experimental work to be done to place 
this, the most recent development, in perspective. To me, as a 
population geneticist, germ-line gene therapy represents the 
ultimate in the manipulation of the biological order. Let's for 
once take our time. 
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